Comparison of beta peak detection algorithms for data-driven deep brain stimulation programming strategies in Parkinson’s disease

Abstract Oscillatory activity within the beta frequency range (13–30 Hz) serves as a Parkinson’s disease biomarker for tailoring deep brain stimulation (DBS) treatments. Currently, identifying clinically relevant beta signals, specifically frequencies of peak amplitudes within the beta spectral band...

Full description

Saved in:
Bibliographic Details
Published inNPJ Parkinson's Disease Vol. 10; no. 1; pp. 150 - 12
Main Authors Baker, Sunderland K, Radcliffe, Erin M, Kramer, Daniel R, Ojemann, Steven, Case, Michelle, Zarns, Caleb, Holt-Becker, Abbey, Raike, Robert S, Baumgartner, Alexander J, Kern, Drew S, Thompson, John A
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group 09.08.2024
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Oscillatory activity within the beta frequency range (13–30 Hz) serves as a Parkinson’s disease biomarker for tailoring deep brain stimulation (DBS) treatments. Currently, identifying clinically relevant beta signals, specifically frequencies of peak amplitudes within the beta spectral band, is a subjective process. To inform potential strategies for objective clinical decision making, we assessed algorithms for identifying beta peaks and devised a standardized approach for both research and clinical applications. Employing a novel monopolar referencing strategy, we utilized a brain sensing device to measure beta peak power across distinct contacts along each DBS electrode implanted in the subthalamic nucleus. We then evaluated the accuracy of ten beta peak detection algorithms against a benchmark established by expert consensus. The most accurate algorithms, all sharing similar underlying algebraic dynamic peak amplitude thresholding approaches, matched the expert consensus in performance and reliably predicted the clinical stimulation parameters during follow-up visits. These findings highlight the potential of algorithmic solutions to overcome the subjective bias in beta peak identification, presenting viable options for standardizing this process. Such advancements could lead to significant improvements in the efficiency and accuracy of patient-specific DBS therapy parameterization.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2373-8057
2373-8057
DOI:10.1038/s41531-024-00762-7